Optimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning
Thoracic Cancer · 2026-04 · 17 (7)
DOI: 10.1111/1759-7714.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 07.04.2026. Verfasst von Qunzhe Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Information Management, Wuhan University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Squamous Cell, Machine Learning. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Key Clinical Projects of Peking University Third Hospital, Project of the China Association for Promotion of Health Science and Technology.
Abstract (Originalsprache)
Background
Stage IB lung squamous‐cell carcinoma (LSCC) lacks individualized survival prediction tools. There's debate on adjuvant chemotherapy's benefit. This study aimed to develop an interpretable machine‐learning model for stage IB LSCC survival prediction and re‐evaluate postoperative chemotherapy's added value.
Methods
A total of 6445 patients with stage IB LSCC diagnosed between 2000 and 2015 were extracted from the SEER database. Patients from 2000 to 2014 ( n = 5740) were split 7:3 into training and internal validation cohorts, while those from 2015 ( n = 705) served as the external validation cohort. Six machine‐learning algorithms (including logistic regression and gradient‐boosting models) were trained to predict 1‐, 3‐, and 5‐year overall survival (OS) with hyperparameter optimization via 10‐fold cross‐validation. SHAP analysis ensured model interpretability, and 1:1 nearest‐neighbor propensity‐score matching evaluated chemotherapy benefit in completely resected patients.
Results
The LightGBM model achieved the best discriminative performance (AUC = 0.834, 0.828, 0.800 for 1‐, 3‐, 5‐year OS) with excellent generalizability in external validation. SHAP analysis identified treatment modality as the top survival predictor; both surgery alone and surgery plus chemotherapy improved survival, but no significant OS difference was observed between the two strategies across all timepoints, consistent across subgroups (age, tumor size, etc.). Propensity‐score matching of 565 patients confirmed similar outcomes (median OS: 64 vs. 62 months; HR = 1.01, 95% CI: 0.82–1.20; p = 0.893).
Conclusion
This study gives individualized survival estimates for stage IB LSCC, backing a risk‐adapted conservative adjuvant treatment approach. High‐risk subgroups got no extra benefit from postoperative chemotherapy, which may help integrate precision medicine and shared decision‐making in early‐stage LSCC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Information Management, Wuhan University, Wuhan, Hubei, China.
- Department of Thoracic Surgery, Peking University Third Hospital, Beijing, China.
- Department of Oncology, Putuo Hospital Affiliated Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Chutong Lin, Yatsu Lam, Shanwu Ma, Guangliang Qiang
Förderung
- the Key Clinical Projects of Peking University Third Hospital
- Project of the China Association for Promotion of Health Science and Technology
Zitieren
APA
Ding, Q., Lin, C., Lam, Y., Guo, F., Ma, S., & Qiang, G. (2026). Optimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning. Thoracic Cancer, 17(7). https://doi.org/10.1111/1759-7714.70270
Vancouver
Ding Q, Lin C, Lam Y, Guo F, Ma S, Qiang G. Optimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning. Thoracic Cancer. 2026;17(7). doi:10.1111/1759-7714.70270
BibTeX
@article{Ding2026,
author = {Ding, Qunzhe and Lin, Chutong and Lam, Yatsu and Guo, Fuxin and Ma, Shanwu and Qiang, Guangliang},
title = {Optimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {7},
doi = {10.1111/1759-7714.70270}
}
EUVIMED